Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations

A Randomized, Placebo-Controlled Trial Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations

The primary purpose of this study is to compare the safety and effectiveness of commercially available dietary supplements believed to increase coenzyme Q10 (CoQ10) concentrations.

An 8-week, randomized, placebo-controlled clinical trial will be conducted comparing the effectiveness of four commercially available dietary supplements on increasing CoQ10 concentrations and self-reported health outcomes.

Study Overview

• Status: Completed
• Conditions: Wellness; Health
• Intervention / Treatment: Other: Placebo; Dietary supplement: Ubiquinol + geranylgeraniol; Dietary supplement: Geranylgeraniol; Dietary supplement: Ubiquinol; Dietary supplement: Ubiquinone

• Study Type: Interventional
• Enrollment (Actual): 150
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • El Dorado Hills, California, United States, 95762
      • True Health Center for Precision Medicine
  • Colorado
    • Centennial, Colorado, United States, 80111
      • Cornerstone Health Community
  • Florida
    • Palm Springs, Florida, United States, 33046
      • CTMD Research
  • Idaho
    • Eagle, Idaho, United States, 83616
      • Functional Medicine of Idaho
  • Texas
    • Houston, Texas, United States, 77082
      • New Dawn Wellness and Medical Center
  • Washington
    • Seattle, Washington, United States, 98122
      • Vida Integrated Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Adult males or females age ≥ 40 years
2. Ability to read and speak English

Exclusion Criteria:

1. Daily use within the past 2 months of any dietary supplements containing CoQ10 or geranylgeraniol (GG)
2. Taking a statin medication within the past 6 months
3. Current daily usage of H2 blockers or PPI medications
4. Current daily use of bisphosphonates
5. Current daily tobacco smoker
6. Known allergies to any substance in the study products
7. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
8. Current diagnosis of a chronic health condition (e.g., cancer, Crohn's disease) deemed clinically contraindicated for the study protocol.
9. Participant in a clinical trial in the previous 30 days.
10. Participants unable to provide consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Other: Placebo; Placebo capsule
Experimental: Geranylgeraniol (Annatto-GG™ 300)	Dietary supplement: Geranylgeraniol; Geranylgeraniol alone
Experimental: Ubiquinol (Jarrow Formulas QH-absorb® 200 mg)	Dietary supplement: Ubiquinol; Ubiquinol alone
Experimental: Ubiquinone (NOW CoQ10 200mg)	Dietary supplement: Ubiquinone; Ubiquinone alone
Experimental: Ubiquinol + geranylgeraniol combination (Designs for Health - CoQnol™ 200)	Dietary supplement: Ubiquinol + geranylgeraniol; Combination of ubiquinol and geranylgeraniol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Plasma Coenzyme Q10	Baseline and 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comprehensive metabolic panel	Alanine aminotransferase (ALT) in units per liter (U/L)	Baseline and 8 weeks
Lipid panel	Low-density lipoprotein (LDL) in milligrams per deciliter (mg/dL)	Baseline and 8 weeks
Patient-Reported Outcomes Measurement Information System (PROMIS) - Global Health	Raw scores range from 4 to 20, with higher scores indicating better global physical or mental health compared to the average	Baseline and 8 weeks
Profile of Mood States - Vigor Subscale	Scores range from 0 to 32, with higher scores indicating better energy levels	Baseline and 8 weeks
Short Form 36 (SF-36) - Vitality Subscale	Scores range from 0 to 100, with higher scores indicating greater vitality	Baseline and 8 weeks

Collaborators and Investigators

• Sponsor: OvationLab

Study record dates

Study Major Dates

• Study Start (Actual): October 12, 2024
• Primary Completion (Actual): September 17, 2025
• Study Completion (Actual): September 17, 2025

Study Registration Dates

• First Submitted: October 10, 2024
• First Submitted That Met QC Criteria: October 10, 2024
• First Posted (Actual): October 15, 2024

Study Record Updates

• Last Update Posted (Actual): March 4, 2026
• Last Update Submitted That Met QC Criteria: March 2, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: CoQ10; Coenzyme Q10; Ubiquinol; Ubiquinone; Geranylgeraniol; GG
• Additional Relevant MeSH Terms: Organic Chemicals; Enzymes and Coenzymes; Coenzymes; Quinones; Benzoquinones; Ubiquinone; ubiquinol; geranylgeraniol
• Other Study ID Numbers: OvationLab

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Deidentified participant data will be made available upon reasonable request.
• IPD Sharing Time Frame: The IPD and supporting information will be available within 6 months after the completion of the study.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No